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Abstract 
Background:  Nonadherence to medication is a recognized problem and may be the most challenging aspect of 
treatment. The weight gain is an important factor that contributed to discontinuation of treatment 
Participants and Methods: A total 88 participants with a DSM-IV diagnosis of schizophrenia who were admitted 
to psychiatric hospital. This study used cross sectional design. The assessments included an interview to obtain 
sociodemographic data, Morisky Medication Adherence Scale (MMAS-8) were examined, for difference based 
on the following body mass index (BMI) categories: normal body mass index (BMI 18,50-24,99) and overweight 
(BMI ≥25). 
Results:  88 subjects were divided into two groups, normal BMI group: high adherence (20.5%), medium 
adherence (63.6%), low adherence (15.9%).   Those overweight group: high adherence (6.8%), medium 
adherence (18.2%), low adherence (75.0%)  
Conclusions: This study found that schizophrenic patients with normal body mass index is more adherence than 
those overweight.   
Keywords: Medication Adherence, Body Mass Index, Overweight, Morisky Medication Adherence Scale 
(MMAS-8) 
 
1. Introduction 
Antipsychotic drugs play an important role in the treatment and to control the symptoms of schizophrenia. 
Effective management of schizophrenia requires a sustained long-term treatment to control symptoms and to 
prevent  relapse.(Higashi, Medic, Littlewood, Diez, Ganstrom, & De Hert, 2013) 
Non-adherence to medication is a major barrier to better treatment outcomes for patients with schizophrenia. At 
least 50% of outpatients with schizophrenia who stop their medication within a year, non-compliance is also a 
major risk factor for relapse. (Weidden, Mackell, & McDonnel, 2004) 
Weight gain associated with long-term treatment  with psychotropic drugs may have an increased risk of 
metabolic disorders and general medical disorders. Among  side effects of antipsychotic treatment, weight gain is 
an important factor that contributes to discontinuation of treatment.(Centorrino, Wurtman, Duca, Fellman, 
Fogarty, Berry at al. 2006) 
Kitabayashi et al. in Japan found from 273 schizophrenic patients,  the proportion of obesity is 30.8%, normal 
weigt is 53.1%, and underweight is 16.1% . (Kitabayashi, Narumuto, & Fukui, 2006). Limousine at al. in French 
found from 5756 individuals with schizophrenia, the prevalence of obesity was 17% . (Limosin, Gasquet, Leguay, 
Azorin, & Rouillon, 2008) Study in Scotland by McCreadi at al, 86 % of patients were overweight or obese. A 
study of 240 patients with schizophrenia or schizoaffective disorder in North America, by Cohn et al, found that 
31% of men and 43% of women are obese. (Newcomer, Fahnestock, & Haupt, 2009) 
 
Research by Weiden found non-adherence with treatment in schizophrenic patients with a normal body mass 
index was 26%, 39% of patients were overweight, and 47% obesity. (Weiden, Mackell, & McDonnel, 2004) 
Nirojini at al. in India found treatment medication non adherence  19 % due to weight gain. (Nirojini, Bollu, & 
Nadendla, 2014) Overweight is a condition where a person's weight exceeds the normal weight. (Sanjaja, & 
Sudikno, 2005) 
Schizophrenic patients may have a higher risk of overweight or obesity caused by a collection of clinical factors, 
physiological, psychosocial, environmental, and possibly additional genetic factors. Negative symptoms of 
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schizophrenia, such as apathy and social withdrawal, and poverty can be clearly hypothesized to have 
contributed to a sedentary lifestyle and a poor diet of this population. (Newcomer, Fahnestock, & Haupt, 2009) 
There was evidence suggest that treatment with psychotropic medication, especially some antipsychotics, can 
induce weight gain and adipose tissue. In general, the treatment of some drugs can lower energy expenditure, 
through sedation or reduction in motor activity, or increasing caloric intake, through increased appetite or 
decrease satiety, could potentially increase the weight gain. (Newcomer, Fahnestock, & Haupt, 2009) 
Many studies about the drug's side effects associated with low levels of treatment adherence and discontinuation 
of treatment, specifically related to obesity, distress due to weight gain. (Dibonevantura, Gabriel, Dupclay, 
Gupta, & Kim, 2012) 
Many studies found that the atypical antipsychotic causes more weight gain compared with typical antipsychotic 
drugs. (Ananth, Parameswaran, & Gunatilake, 2004)  
 
2. Methods 
2.1. Participants 
The inclusions criteria were (a) aged 20-50 years, (b) DSM-IV criteria for schizophrenia, (American Psychiatric 
Association, 1994) (c) requiring atypical antipsychotic, (d) stabilization phase, (e) insight 3 or higher, (f) ability 
to read and write in Indonesian, cooperative and willingness to give informed consent. Exclusions criteria were 
(a) current pregnancy or lactating, (b) having cronic medical illness, (c) substance use (except caffeine and 
nicotine) 
 
2.2. Procedure 
Participants were out-patients, recruited from Sumatera Utara Mental Hospital in Medan, Indonesia from August 
to September 2015. Every eligible patient were given an explanation about the study, and provided written 
informed consent,  they asked to give demographic data,  measured body mass index. Each patient with a normal 
BMI (44 patients) and overweight  (44 patiens) were asked to fill out a questionnaire Morisky Medication 
adherence Scale (MMAS-8) to measure treatment adherence. 
 
2.3. Instrument 
Morisky Medication Adherence Scale (MMAS-8) developed from the original four item Morisky scale was 
published. The first seven items are dichotomous response categories with yes or no and the last item was a five 
point Likert response. Compared to original Morisky scale, it has the following features: 1) The adding four 
items are trying to identify and address the circumstances or situations related to adherence behavior; 2) 
Importantly, it has much better psychometric properties: sensitivity and specificity are 93% and 53%, 
respectively and Cronbach’s alpha value is 0.83 that is above the acceptance threshold. Afterwards, MMAS-8 
has become popular and commonly used in various clinical settings and different populations, as well as been 
translated and validated in foreign countries. (Tan, Patel, & Chang, 2014) 
 
2.4. Data analysis 
All the statistical analyses were performing  using SPSS version. 17.0. Demographic data were analysed using 
chi-squared or t-test as appropriate. (Dahlan, 2009) 
 
2.5. Ethical clearence and permission 
The Research Ethics Committee of University of Sumatera Utara, Indonesia,  reviewed and provided ethical 
approval for the study.    
 
3. Results 
Clinical and demographic characteristics are displayed in table 1. 
The difference of medication adherence in schizophrenic patients between with normal body mass index and 
overweight are displayed in table 2. We found that there is a significant difference between the level of 
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medication adherence in schizophrenic patients with normal body mass index and overweight with p = 0.001.    
 
4. Discussion 
Consistent with our hypotheses, among schizophrenic patients with normal body mass index and overweight, we 
found the level of treatment adherence of schizophrenic patients with a normal body mass index most likely to 
report higher adherence by 28 people (63.6%). Those in the overweight had low level of adherence by 33 people 
(75.5%).  It is consistent with study by Nirojini at al. in India (2013), Weiden at al.  (2004) 
Dissatisfaction with weight loss have been associated with low medication adherence. (Wong, 2010) Patients 
who are obese are 2.5 times more likely to stop taking the drug compared with those not obese.(Weiden, Mackell, 
& McDonnel, 2004) 
 
5. Limitation 
Limitations of this study are not assess other factors that affect medication adherence. 
 
6.Conclusion 
The level of medication adherence in the group with normal body mass index had  higher medication adherence 
than those with overweight. There is a significant difference level of medication adherence in schizophrenic 
patients between normal body mass index and overweight . 
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Merital status, n (%) 
- Married                                               6 (13.6)                             7 (15.9)               0.09 
- Single                                                 38 (86.4)                           37 (84.1)             
Employment, n (%) 
- Employed                                           16 (36.4)                           19 (43.2)              0.51 
- Not employed                                     28 (63.6)                           25 (56.8)            
Level of education,  n (%) 
- Less than senior high school               13 (29.5)                           11  (25.0)            0.63 
-
 Senior high school or higher               31 (70.5)                           33 (75.0)                                         
Addres 
- Medan                                                 18 (40.9)                            20 (45.5)            0.66 
- Out of  Medan                                     26 (59.1)                            24 (54.5) 
Antipsychotic , n (%) 
- Risperidone  4mg                                  8 (18.2)                           10 (22.7)             0.59   
- Risperidone 4mg+ Clozapine 25mg    36 (81.8)                           34 (77.3) 
Insight 
-  III                                                        34 (77.3)                           38 (86.4)             0.26 
-  IV                                                       10 (22.7)                              6 (13.6) 
Duration of desease 
   -Mean ± SD                                             6.05 ± 3,67                       8.80 ± 4.68         0.06 
Number  of relapse 
   -Mean ± SD                                             2.55 ± 0.66                       2.73 ± 0.78         0.15 
________________________________________________________________ 
 
 
Tabel. 4.2. Difference of Medication adherence betweenSchizophrenic patients with normal 
body mass index and overweight 
 
 
Table 1. Samples demographics (N = 88) 
 
 
 
Normal Body 
Mass Index (n=44) 
Overweight 
(n=44) 
    p 
 
Age (Year) 
mean  ± SD                                        
 
31.93 ± 6.14 
 
34.30 ±7.17 
 
0.17 
Gender , n (%)  
Male                                                                             
Female  
 
32 (72.7) 
12 (27.3) 
 
26 (59.1) 
18 (40.9) 
 
0.18 
Merital status, n (%) 
Married                                                                                          
Single                                               
 
6 (13.6) 
38 (86.4) 
 
7 (15.9) 
37 (84.1) 
 
0.09 
Employment, n (%) 
Employed                                                                               
Not employed                                    
 
16 (36.4) 
28 (63.6) 
 
19 (43.2) 
25 (56.8) 
 
0.51 
Level of education,  n (%) 
Less than senior high school                                                      
Senior high school or higher             
 
13 (29.5) 
31 (70.5) 
 
11  (25.0) 
33 (75.0) 
 
0.63 
 Addres 
In Medan                                                                                         
Out of  Medan                                   
 
18 (40.9)
26 (59.1) 
 
20 (45.5) 
24 (54.5) 
 
0.66 
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Antipsychotic , n (%) 
Risperidone  4mg                                                                          
Risperidone 4mg+ Clozapine 25mg 
 
8 (18.2)
36 (81.8) 
 
10 (22.7) 
34 (77.3) 
 
0.59  
Insight 
 III                                                                                               
 IV                                                    
 
34 (77.3)
10 (22.7) 
 
38 (86.4) 
6 (13.6) 
 
0.26 
 
Duration of desease 
   -Mean ± SD                                         
 
6.05 ± 3,67 
 
8.80 ± 4.68 
 
0.06 
 Number  of relapse 
   -Mean ± SD                                         
 
2.55 ± 0.66 
 
2.73 ± 0.78 
 
0.15 
 
 
Table.  2. The Difference of Medication Adherence  in Schizophrenic patients between normal body mass 
index and overweight 
 
Level of medication adherence    Normal BMI          Overweight            p 
                                                              n(%)                n (%) 
High                                 9 (20.5)             3 (  6.8)       
Medium                           28 (63.6)            8 (18.2)             0.001 
Low                                   7 (15.9)            33 (75.0) 
 
